Company* |
Funding |
Amount (M) | Type# | Details (Date) |
| | ||||
Aastrom |
National Cancer Institute | $0.11 |
Phase I SBIR grant | To study the AastromReplicell System in enhancing the immunostimulatory potency of dendritic cell-based cancer vaccines (9/30) |
Acambis plc |
National Institute of Allergy and Infectious Diseases | $131 |
Contract award |
$76M is for development and manufacturing of a modified vaccinia ankara smallpox vaccine, totaling 500,000 doses; a $55M option covers up to 2.5M more single-dose vials (9/30) |
Accelrys Inc. |
Northrop Grumman Corp. |
ND | Subcontract award |
Accerlerys will use statistical modeling technology to help research and develop bioagent detectors for the U.S. Department of Homeland Security (9/1) |
Adenosine |
Department of Health and Human Services | $0.64 |
SBIR grant |
The two-year grant will support work with the University of Virginia on ATL-146e for treating inflammatory bowel disease (7/20) |
Advanced |
National Institutes of Health | $0.687 |
Phase I SBIR grants | Three grants to support advancement of gene transfer technology for treating prevalent eye diseases (8/5) |
Agencourt |
National Institutes of Health | ND |
Contract renewal |
Two-year renewal under which Agencourt will provide sequencing services for the Mammalian Gene Collection project and the Cancer Genome Anatomy Project at the NIH (8/31) |
AlphaVax |
National Institute of Allergy and Infectious Diseases | $4.8 |
Development grant | The three-year grant is for early development of a SARS vaccine (9/13) |
Altor |
National Cancer Institute |
$1 | Phase II SBIR grant |
Two-year grant will support advancement of soluble T-cell antigen receptor fusions toward clinical development as cancer therapeutics (9/20) |
Anadys |
National Institutes of Health | $1.2 |
Phase II SBIR grant | The two-year grant will support development of antibacterials that inhibit ribosomal function in drug-resistant bacteria (9/21) |
Antex Biologics |
National Institute of Allergy and Infectious Diseases | $2 |
Grant |
The grant will be distributed over three years to support development of a dry formulation of the company's Helicobacter pylori vaccine candidate (7/9) |
Arexis |
European Union |
ND | Sixth Framework program funding |
To support the program on bile salt-stimulated lipase, an enzyme present in human milk, for neonatal applications (9/22) |
Avant Immuno- |
Department of Defense |
$2.8 | Funding support |
Appropriations bill contained funding support for continued development of an oral combination vaccine to protect against anthrax and plague (7/26) |
Bavarian |
National Institute of Allergy and Infectious Diseases | $141 |
Contract |
$100M of the contract is for the company to produce 500,000 doses of Imvamune smallpox vaccine within 11 months; the government has an option to buy another 2.5M doses of the MVA vaccine for $41M (9/30) |
Biotie Therapies |
Tekes (National Technology Agency of Finland) | €1.4 (US$1.7) |
Funding support | The money is designed to cover 50% of the cost of a Biotie research program on integrin through February 2006 (7/5) |
Blue |
National Institute of General Medical Science and the National Human Genome Research Institute | $0.138 |
Phase I SBIR grant | For development of a "universal" restriction enzyme system; for assembling large DNA molecules by ligation of sticky-ended fragments (9/9) |
Bolder |
National Cancer Institute | $0.92 |
Phase I and II SBIR grants | A Phase II grant of $819,961 is for studying long-acting endostatin for treating cancer; a $100,000 Phase I grant is for long-acting VEGF-binding proteins for treating cancer (9/1) |
Bolder |
National Institute of Neurological Disorders and Stroke | $0.75 |
Phase II SBIR grant | To support optimization and manufacturing of a long-acting beta interferon candidate for multiple sclerosis (8/18) |
Caprion |
National Institute of Allergy and Infectious Diseases | $13.1 |
Contract award |
Five-year contract in biodefense research to study molecular events that enable bacteria to subvert the immune system (8/10) |
Cellerant |
National Institute of Allergy and Infectious Diseases | $0.8 |
SBIR grant |
For work on using adult hematopoietic stem and progenitor cells to treat those exposed to lethal doses of radiation (9/29) |
Ceregene |
The ALS Association |
ND | Funding support |
The ALSA will support preclinical studies at Ceregene on viral delivery of insulin-like growth factor 1 for amyotrophic lateral sclerosis (9/15) |
Cerus |
National Institute of Allergy and Infectious Diseases | $3.8 |
Grant |
Three-year grant to develop an anthrax vaccine with greater potency than existing vaccines; $1.4M will be awarded the first year (7/28) |
Chemical |
National Institutes of Health | ND |
Phase I STTR grant |
Joint grant is to support discovery of small-molecule inhibitors of the melanocortin-2 receptor, for adrenal gland disorders (8/19) |
Chiron Corp. |
National Institute of Allergy and Infectious Diseases | ND |
Contract award |
Chiron will produce up to 40,000 doses of an H9N2 influenza vaccine; the NIAID will conduct clinical studies to explore safety and immunogenicity (8/17) |
Coley |
National Institute of Allergy and Infectious Diseases | $16.9 |
Contract award |
Five-year contract will fund development of immune-activating drug targeting Toll-like receptors for defense against bioterror agents (9/21) |
CombiMatrix |
Department of Defense | $2.3 |
Contract award |
The funding increase brings to $5.9M the amount awarded for development of a sensor system for detecting threatening agents (7/22) |
Commonwealth |
Undisclosed |
$1.2 | Contract award |
Provided fourth year of funding to develop reagents that can be used for detecting select agent pathogens (8/12) |
Commonwealth |
Undisclosed |
$0.8M | Contract award |
To conduct molecular assays on DNA extracted from samples taken from a two-year human clinical trial (8/12) |
Commonwealth |
Vistronix Inc. |
$0.15M | Contract award |
Add-on to contract under which CBI uses assays to test for bioagents in mail-sorting facilities (7/1) |
Commonwealth |
BEI Resources |
$0.23M | Contract award |
Details on the biodefense-related contract were not disclosed (7/1) |
Commonwealth |
Undisclosed U.S. government agency | $0.8M |
Contract award |
Two-year program involves developing new laboratory analyses for select agent pathogens; details were not disclosed (7/1) |
Cryptome |
AusIndustry (Australia) |
A$1.95 (US$1.34) | R&D START grant |
The grant will fund up to 50 percent of preclinical development of CR001, a naturally occurring peptide, as an alternative to current thrombosis drugs (8/30) |
Curis Inc. |
Spinal Muscular Atrophy Foundation | $5.4 |
Grant |
Three-year grant will support work at Curis to develop motor neuron assays and use them to screen for potential drug candidates for treating SMA (9/7) |
Cyntellect Inc.* |
Not disclosed | $1.5 |
Phase II SBIR grant | For continued development of RNA interference applications on its LEAP platform (9/14) |
Cytogen Corp. (CYTO) |
Department of Defense | $0.1 |
Grant |
Thomas Jefferson University was awarded a grant to study Cytogen's Quadramet with hormonal therapy in prostate cancer patients at high risk of the disease spreading to the bone (8/9) |
Diffusion |
Department of Defense |
$1 | DoD appropriation |
To support the preclinical development of transodium crocetinate for treating illnesses characterized by hypoxia (9/8) |
Diffusion |
Office of Naval Research |
$1.2 | Grant |
To support the preclinical development of transodium crocetinate for treating hemorrhagic shock (7/28) |
Discovery |
National Institutes of Health | $24 |
Contract award |
To set up and maintain a small-molecule repository to manage and provide up to 1 million compounds to NIH screening centers as part of the NIH Roadmap; the contract is worth $24M if it runs its full term through 2008 (8/23) |
Diversa Corp. |
National Institute of Allergy and Infectious Diseases | $1 |
Grant |
Diversa was awarded $1M for the first year of work to discover and develop antibodies to diagnose and treat severe acute respiratory syndrome (9/8) |
DNA 2.0 Inc.* |
National Human Genome Research Institute | ND |
SBIR grant |
The grant will support work to increase the fidelity and reduce the cost of synthetic DNA manufacture (9/21) |
DOR BioPharma |
National Institute of Allergy and Infectious Diseases | $5.2 |
Grant |
For further development of DOR's ricin vaccine, RiVax (9/13) |
Emergent |
Oklahoma Center for Advancement of Science and Technology | $0.27 |
Grant |
Pure Protein LLC, an Emergent portfolio company, will use the money to develop new assays to validate epitopes it discovered (8/3) |
Epimmune Inc. |
National Institute of Allergy and Infectious Diseases | $2.8 |
Contract award |
The NIAID exercised a three-year contract option for Epimmune to conduct preclinical development of a multi-epitope malaria vaccine (7/13) |
EpiVax Inc.* |
National Institute of Allergy and Infectious Diseases | $0.86 |
BioDefense Phase I SBIR grant | For development of a genome- derived, epitope-driven tularemia (Francisella tularensis) vaccine (9/13) |
Gambro AB |
U.S. Department of Defense |
$2 | Grant |
Gambro subsidiary Navigant Biotechnologies Inc. will use the money to develop a transport- able pathogen- eduction and blood safety system, applicable to use by the military (8/25) |
Genaera |
National Eye Institute | $0.1 |
Phase I SBIR grant | To further develop squalamine-related aminosterols as anti-angiogenics for treating wet age- related macular degeneration (9/30) |
Genaera Inc. |
National Institute of Diabetes and Digestive and Kidney Diseases | $0.1 |
Phase I SBIR grant | To support initial development of a small-molecule aminosterol (trodusquemine) for treating obesity (9/29) |
Genomatica |
Department of Energy |
$0.75 | Phase II SBIR grant |
To enhance the SimPheny software platform for use in supporting metabolic research (9/28) |
GenPhar Inc.* |
U.S. Army | $4.9 |
Contract expansion | Funding increased from $1.1M to $6M over two years for work on multivalent vaccines for Marburg and Ebola viruses (7/30) |
Genetronics |
National Institutes of Health |
$0.1 | Phase I SBIR grant |
To support research in the use of electroporation technology in vascular gene therapy (8/31) |
Hematech |
U.S. Army's Joint Vaccine Acquisition Program | $3 |
Funding support |
Appropriations bill included funding to support a large-scale bovine production system for fully human polyclonal antibodies (7/28) |
ID Biomedical Corp. (Canada; TSE:IDB) | National Institutes of Health |
$9.5 | Grant |
To support further development and early trials of its cell culture-based influenza vaccine (9/29) |
ID Biomedical Corp. (Canada; TSE:IDB) | National Institutes of Health |
$8 | Grant |
Up to $8M will be awarded for development of a nasally administered plague vaccine based on the company's Proteosome delivery technology (9/21) |
ID Biomedical |
Canadian government |
C$30 (US$23.3) | Contract award |
ID Biomedical was selected to supply meningitis C vaccine to the Canadian government over two years; theC$30M value includes a third-year option (9/13) |
Illumina Inc. |
National Institute of Allergy and Infectious Diseases | $1.2 |
Phase II SBIR grant | For continued development of high-multiplex arrays to profile protein activity in small volumes of cells or biological fluids (8/11) |
Infectech Inc. |
Ohio Agricultural Research and Development Center | ND |
Research grant |
Ohio State University researchers will use the grant to test a diagnostic for Mycobacterium avium; the technology OSU will use is owned by Infectech (8/30) |
Introgen |
National Cancer Institute | $0.7 |
Grant |
The three-year grant will support evaluation of the anti-angiogenis properties of mda-7/IL-24; colborators at M.D. Anderson Cancer Center will lead the research (9/21) |
Macropore |
National Institutes of Health | $0.75 |
SBIR grant |
For second phase of a project to study the role of adipose-derived regenerative cells in treating heart attack (7/27) |
Molecular |
National Institutes of Health | ND |
Grant |
To develop molecular imaging agents to detect and monitor the activity of angiotensin-convering enzyme in patients with congestive heart failure (8/26) |
MycoLogics |
Naitonal Institutes of Health | ND |
Phase I SBIR grant |
To identify a lead drug compound for human trials for the treatment of leishmaniasis (8/20) |
Myriad Genetics Inc. (MYGN) | National Institute of Allergy and Infectious Diseases | $14.2 |
Contract award |
Myriad will characterize pathogen-host protein interactions to discover targets for new vaccines, drugs and diagnostics; the interaction and validation data will be made available to the R&D community, while Myriad retains the rights to any resulting diagnostic and therapeutic targets (7/8) |
Nanospectra Biosciences Inc.* | National Institute of Standards and Technology | $2 |
Advanced Technology Program award | To develop an integrated approach to the diagnosis and treatment of cancer using a new class of near-infrared absorbing nano-particles called nanoshells (9/29) |
Neuro3d* |
The French Agency for Innovation (ANVAR) | €0.9 (US$1.1) |
Research support | To support further development of the Phase I phosphodiesterase- 4 inhibitor ND1251 for treating depression (7/15) |
NsGene A/S* |
Michael J. Fox Foundation for Parkinson's Research | $3 |
Grant |
To support proof-of-concept studies of encapsulated cell therapy in Parkinson's disease; the funding will be given as mile-stones are achieved (7/1) |
Northfield |
Department of Defense |
$1.4 | Defense appropriations funding |
For continued development of PolyHeme, a human hemoglobin-based blood substitute; for potential use on battlefields (8/26) |
Nura Inc.* |
National Institutes of Health | $1 |
Fast-track grant |
The grant will be used to apply technology in G protein- coupled receptors to study anxiety (9/22) |
OriGene |
National Human Genome Research Institute | ND |
Phase I SBIR grant |
The award will support work with the company's TrueClone collection of full-length cDNA clones (9/23) |
Pain |
National Institutes of Health | $0.1 |
Innovation research grant | The grant will support company research and development in neuropathic pain (7/12) |
Paratek |
National Institute of Allergy and Infectious Diseases | $2 |
Phase II SBIR grant | Two-year grant to support development of tetracycline-based compounds for malaria (7/7) |
Perlegen |
National Human Genome Research Institute | $6 |
Grant |
Perlegen will genotype more than 2.25M single nucleotide polymorphisms in 270 samples from four populations being studied by the HapMap Project (9/30) |
Perlegen |
National Institution Aging | ND |
Grant |
For a whole-genome association study of Alzheimer's disease (9/13) |
Perlegen |
National Institute of Mental Health | ND |
Grant |
For the first phase of a high-density genome-wide study to determine the genetics of autism; it will use DNA samples collected by the Autism Genetic Resource Exchange (8/19) |
Pharmos |
Office of the Chief Scientist (Israel) | $0.482 |
Grant
|
To support development of drug candidates from its program on peripheral cannabinoid-2 recep- tor agonists (9/7) |
ProteomTech |
National Cancer Institute |
$0.75 | Phase II SBIR grant |
To support development of an anti-angiogenesis protein drug, vascular endothelial growth inhibitor (8/24) |
ProteoTech |
National Institute of Arthritis and Musculoskeletal and Skin Disorders | $0.265 |
Phase I SBIR grant | To fund further development of small molecules believed to inhibit a variety of amyloid diseases (9/24) |
ProteoTech |
National Institute on Aging | $0.52 |
Phase I SBIR grant | To analyze the regulation of proteoglycan genes and proteins and their role in the pathogenesis of amyloid plaque development in Alzheimer's disease (8/4) |
PTC |
Parent Project Muscular Dystrophy | $1 |
Grant |
PTC will apply its GEMS technology to identify small-molecule compounds to treat Duchenne muscular dystrophy; PTC and PPMD already selected target genes with potential relevance (9/2) |
QRxPharma |
Australian Research Council | $3.2 |
Linkage Discovery grant | QRxPharma and the University of Queensland will use the money for their work to identify active compounds by studying the venom of Australian snakes (7/7) |
Receptor |
National Institute of Standards and Technology | $2 |
Advanced Technology Program award | Three-year award will fund development of a profiling and immunotherapy platform targeting breast cancer (9/30) |
Revivicor Inc.* |
National Institute of Standards and Technology | $1.8 |
Advanced Technology Program award | To use gene knockout and somatic nuclear transfer technologies to inactivate antibody-producing genes in pigs, and replacing them with human equivalents (9/29) |
RheoGene Inc.* |
National Institute of Standards and Technology | $2 |
Advanced Technology Program award | To develop techniques for site-specific insertion and control of therapeutic genes in human adult neural stem cells to treat incurable ocular diseases (9/29) |
Samaritan |
National Institute of Neurological Disorders and Stroke | $0.188 |
STTR grant |
The grant supports work at Samaritan and Georgetown University on a diagnostic based on the correlation between DHEA pre-cursor levels and Alzheimer's disease (7/12) |
Sangart Inc.* |
National Heart, Lung and Blood Institute and the Department of Defense | $1.3 |
Grant |
The grant will support research of the oxygen carrier Hemospan for hypovolemic circulatory collapse (9/8) |
Scynexis Inc.* |
National Institute on Drug Abuse | $3 |
Contract award |
Award for up to $3M to produce bulk drug substances for NIDA's program to develop medications for illicit drug dependency (7/22) |
SIGA |
U.S. Air Force |
$4 | Contract award |
SIGA was named prime contractor on a $4M project to create systems for the rational development of products against biological terrorism threats (9/14) |
SIGA |
National Institutes of Health | $12 |
Grants |
SIGA got two two-year grants to support development of biowarfare defense assets in the area of antivirals that were acquired from ViroPharma Inc. (8/25) |
Sinovac Biotech |
Chinese government |
$1.2 | Research support |
The award increases to $2.3M government funding support for the company's SARS vaccine development program (7/20) |
SomaGenics |
National Institute of General Medical Sciences | $0.315 |
Grant |
For in vitro selection of the RNA Lassos capable of specific binding to mRNA targets (8/1) |
StemCells Inc. |
National Institutes of Health | $0.465 |
STTR grant |
StemCells collaborators at the McLaughlin Research Institute got the grant to study human central nervous system stem cells in mouse models of Alzheimer's disease (9/20) |
StemCells Inc. |
National Institutes of Health | $1.4 |
Grant |
StemCells collaborators at the University of California at Irvine got the grant to study human central nervous system stem cell grafts in treating spinal cord injuries (9/20) |
Transkaryotic |
FDA's Office of Orphan Products Development | $0.3 |
Development grant | To support an ongoing pivotal trial of the enzyme-replacement therapy iduronate-2-sulfatase for Hunter's syndrome (9/28) |
Velcura |
National Institute of Diabetes and Digestive and Kidney Diseases | $1.45 |
Grant |
To support research on the mechanisms by which primitive cells develop into mature bone-forming cells (7/30) |
Verta Ltd.* |
U.S. Civilian Research and Development Foundation | $0.3 |
Grant |
To evaluate the therapeutic potential of SCV-07 in a hepatitis C virus proof-of-concept trial in Russia (8/25) |
Znomics Inc.* |
National Human Genome Research Institute and the National Institute of Diabetes and Digestive and Kidney Diseases | $1.53 |
Phase II SBIR grant | The grant will fund completion of the company's zebrafish insertional mutation library for use in drug and target discovery (9/22) |
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
# SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | ||||
